

1638

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:



By:

Jennifer Mahoney *AK*
Jennifer L. Mahoney

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****IN RE APPLICATION OF:**

Soos, et al.

APPLICATION NO.: 10/029,890

FILED: December 21, 2001

FOR: ORALLY-ADMINISTERED INTERFERON-TAU COMPOSITIONS AND METHODS

EXAMINER: Not yet Assigned

ART UNIT: 1638

CONFIRMATION NO.: 6039

RECEIVED

AUG 09 2002

TECH CENTER 1600/200

Information Disclosure Statement Within Three Months of Application Filing or Before First Action – 37 CFR 1.97(b)

Assistant Commissioner for Patents
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 CFR 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- Copies of the following references are enclosed:
- All cited references
 - References marked by asterisks
 - The following:
- Copies of the following references can be found in parent U.S. Application No. 08/616,904:
- All cited references
 - References marked by asterisks
 - The following:

- The following references are not in English. For each such reference, the undersigned has enclosed (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference, (iii) a copy of a reference which appears to be an English-language counterpart, or (iv) an English-language abstract for the reference prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.
- All cited references
 References marked by ampersands
 The following:

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 CFR 1.704(d))

- The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,

Date: August 1, 2012

Judy M.
 Judy M. Mohr
 Registration No. 38,563


Correspondence Address:

Customer No. 22918
 (650) 838-4300

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)



Page 1 of 2

ATTY. DOCKET NO.
55600.8003.US00SERIAL NO.
10/029,890

APPLICANT

Soos, et al.

FILING DATE
December 21, 2001GROUP
1638

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4,997,646	03/05/91	Hansen, et al.			RECEIVED
	5,019,382	05/28/91	Cummins, Jr.			AUG 09 2002
	5,206,219	04/27/93	Desai			TECH CENTER 1600/2900
	5,372,808	12/13/94	Blatt, et al.			
	5,705,363	01/06/98	Imakawa			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
	WO 90/09806	09/07/90	PCT			
	WO 94/10313	05/11/94	PCT			
	WO 95/27499	10/19/95	PCT			
	WO 95/27502	10/19/95	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


	Amidon, G.L., et al., <i>Peptide and Protein Drug Delivery</i> 43:146-152 (1998).
	Anonymous, <i>Lancet</i> 336(8720):935 (1990).
	Aranason, et al., <i>Clinical Neuropharmacology</i> 17(16):495-547, (1994).
	Banga, A.K., "Oral Delivery of Peptide and Protein Drugs," (Chapter 8) in <u>THERAPEUTIC PEPTIDES AND PROTEINS: FORMULATION, PROCESSING, AND DELIVERY SYSTEMS</u> , Technomic Publishing Co., Inc., Lancaster, PA, pp. 217-243 (1995).
	Brod, S.A., and Burns, D.K., <i>Neurology</i> 44:1144-1148 (1994).
	Brod, S.A., et al., <i>J. Interferon Res.</i> 15:115-122 (1995).
	Brod, S., et al., <i>J of Interferon and Cytokine Research</i> 15(2):115-122 (1995).
	Brod, S. and Khan, M., <i>J of Autoimmunity</i> 9(1):11-20 (1996).
	Caban, J., et al., <i>Archivum Immunologiae et Therapiae Experimentalis</i> 41(3-4):229-235 (1993).
	Cummins, J.M., et al., <i>Veterinary Immunology and Immunopathology</i> 45(3-4):355-60 (1995).
	Cummins, J.M., <i>J. Biol. Response Modif</i> 7(5):513-523 (1988).
	Degre, M. and Bukholm, G., <i>J of Biological Regulators and Homeostatic Agents</i> 9(1):15-20 (1995).
	Dermer, G.B., <i>Bio/Technology</i> 12:320, (1994).
	Fleischmann, W., et al., <i>Proceedings of the Society for Experimental Biology and Medicine</i> 201(2):200-7 (1992).

COPY OF PAPERS
ORIGINALLY FILED

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)



Page 2 of 2

ATTY. DOCKET NO.
55600.8003.US00SERIAL NO.
10/029,890

APPLICANT

Soos, et al.

FILING DATE
December 21, 2001GROUP
1638

	Freshney, R.I., <u>CULTURE OF ANIMAL CELLS: A MANUAL OF BASIC TECHNIQUE</u> , Alan R. Liss, Inc., NY, NY, pages 3-4, (1983).
	Georgiades, J.A., <i>Archivum Immunologiae et Therapiae Experimentalis</i> 44(1):11-22 (1996).
	Georgiades, J.A., <i>Archivum Immunologiae et Therapiae Experimentalis</i> 41(3-4):259-265 (1993).
	Hutchinson, V.A., et al., <i>Mol Biother</i> 2(3):160-164 (1990).
	Imakawa, K., et al., <i>Nature</i> , 330:377-379, (1987).
	Johnson, H.M., et al., <i>Scientific American</i> 270(5):40-47 (1994).
	Koren, S., et al., <i>Proceedings of the Society for Experimental Biology and Medicine</i> 204(2):155-164 (1993).
	Lecce, J.G., et al., <i>Mol Biother</i> 2(4):211-216 (1990).
	Moore, B., et al., <i>Veterinary Immunology and Immunopathology</i> 49(4):347-358 (1996).
	Nelson, P.A., et al., <i>Annals of the New York Academy of Sciences</i> , 778:145-155 (1996).
	Pontzer, C.H., et al., <i>Biochem. Biophys. Res. Commun.</i> , 152(2):801-807, (1988).
	Pontzer, C.H., et al., <i>Cancer Research</i> 51:5304-5307 (1991).
	Qi, Y., et al., <i>Hum Antibod Hybridomas</i> 7(1):21-26 (1996).
	Ranade, V.V. and Hollinger, M.A., <u>DRUG DELIVERY SYSTEMS</u> , CRC Press Inc. Boca Raton, Florida pp. 127-128, 151 (1996).
	Shiozawa, K., et al., <i>Arthritis & Rheumatism</i> 39(9):S63 (1996).
	Soos, J.M., and Johnson, H.M., <i>J. Interferon Res.</i> 15:39-45 (1995).
	Soos, J.M., et al., <i>J. Immunol.</i> 155:2747-2753 (1995).
	Soos, J.M., et al., <i>FASEB J. Experimental Biol.</i> 9(4):Abs. No. 5940 (1995).
	Weiss, R.C., et al., <i>J. Am. Vet. Med. Assoc.</i> 199(10):1477-1481 (1991).
	Wills, R.J., et al., <i>Journal of Interferon Research</i> 4(3):399-409 (1984).
	Witt, P., et al., <i>J of Interferon Research</i> 12(6):411-413 (1992).
	Zielinska, W., et al., <i>Archivum Immunologiae et Therapiae Experimentalis</i> 41(3-4):241-251 (1993).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.